HC Wainwright Reiterates “$75.00” Price Target for Sarepta Therapeutics (SRPT)

HC Wainwright set a $75.00 price target on Sarepta Therapeutics (NASDAQ:SRPT) in a research report released on Wednesday. The firm currently has a buy rating on the biotechnology company’s stock.

Several other research analysts also recently weighed in on the stock. Credit Suisse Group increased their price target on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an outperform rating in a research report on Thursday, September 7th. Nomura reissued a buy rating and issued a $84.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, September 5th. Zacks Investment Research raised shares of Sarepta Therapeutics from a hold rating to a buy rating and set a $54.00 price objective for the company in a research note on Monday, October 30th. Needham & Company LLC reaffirmed a buy rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Finally, Oppenheimer reaffirmed a buy rating and set a $76.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and nineteen have assigned a buy rating to the company. The stock has an average rating of Buy and an average price target of $63.88.

Sarepta Therapeutics (NASDAQ:SRPT) opened at $54.87 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. Sarepta Therapeutics has a 52-week low of $26.26 and a 52-week high of $59.95. The firm has a market cap of $3,736.38, a P/E ratio of -26.77 and a beta of 1.37.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The business had revenue of $45.95 million for the quarter, compared to the consensus estimate of $41.29 million. During the same period last year, the firm earned ($0.95) earnings per share. sell-side analysts predict that Sarepta Therapeutics will post -3.11 EPS for the current fiscal year.

In other news, SVP Shamim Ruff sold 10,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $55.00, for a total value of $550,000.00. Following the transaction, the senior vice president now owns 37,045 shares of the company’s stock, valued at approximately $2,037,475. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Douglas S. Ingram bought 38,138 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were bought at an average cost of $52.44 per share, for a total transaction of $1,999,956.72. Following the transaction, the chief executive officer now owns 420,196 shares in the company, valued at approximately $22,035,078.24. The disclosure for this purchase can be found here. 9.60% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Ladenburg Thalmann Financial Services Inc. grew its position in Sarepta Therapeutics by 140.9% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 2,493 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth approximately $204,000. Ameritas Investment Partners Inc. lifted its stake in Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 271 shares during the period. Cubist Systematic Strategies LLC lifted its stake in Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 2,474 shares during the period. Finally, Strs Ohio acquired a new stake in Sarepta Therapeutics during the 3rd quarter valued at approximately $208,000. 82.02% of the stock is currently owned by institutional investors.

WARNING: This article was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2018/01/06/hc-wainwright-reiterates-75-00-price-target-for-sarepta-therapeutics-srpt.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

What are top analysts saying about Sarepta Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sarepta Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit